Brain scans reveal how ketamine quickly lifts severe depression

A new study published in Molecular Psychiatry on March 5, 2026, sought to clarify this mystery. The research was led by Professor Takuya Takahashi of the Department of Physiology at Yokohama City University Graduate School of Medicine in Japan. The team used an advanced positron emission tomography (PET) imaging method to directly observe changes in glutamate α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR). This receptor is a key protein that helps regulate communication between brain cells and plays an important role in synaptic plasticity and glutamatergic signaling in patients receiving ketamine.

Prof. Takahashi explained, "Although ketamine has shown rapid antidepressant effects in patients with treatment-resistant depression, its molecular mechanism in the human brain has remained unclear."

Visualizing Brain Receptors With a Novel PET Tracer

The research relied on a PET tracer developed earlier by the team, known as [¹¹C]K-2. This tracer allows scientists to visualize cell-surface AMPAR directly in the living human brain. Previous laboratory and animal studies suggested that ketamine's antidepressant effects involve AMPAR activity. The new research provides the first direct evidence of this process occurring in humans.

To conduct the study, the researchers combined data from three registered clinical trials carried out in Japan. The study group included 34 patients diagnosed with TRD and 49 healthy participants who served as controls.

Patients received intravenous ketamine or a placebo over a two-week period. PET brain imaging was performed before the start of treatment and again after the final infusion. This approach allowed researchers to compare changes in AMPAR levels and distribution in the brain over time.

Region-Specific Brain Changes Linked to Symptom Relief

The results showed that people with TRD had widespread abnormalities in AMPAR density compared with healthy participants. These differences appeared in specific brain regions rather than across the brain as a whole.

Ketamine did not produce uniform changes throughout the brain. Instead, improvements in depressive symptoms were linked to dynamic, region-specific adjustments in AMPAR levels. Some cortical areas showed increased receptor density, while reductions were seen in regions associated with reward processing, especially the habenula. These region-specific shifts were strongly connected to improvements in patients' depressive symptoms.

"Ketamine's antidepressant effect in patients with TRD is mediated by dynamic changes in AMPAR in the living human brain," Prof. Takahashi explained. "Using a novel PET tracer, [¹¹C]K-2, we were able to visualize how ketamine alters AMPAR distribution across specific brain regions and how these changes correlate with improvements in depressive symptoms."

These observations provide direct human evidence that supports mechanisms previously identified in animal studies and connects them to real clinical antidepressant effects.

Potential Biomarker for Predicting Treatment Response

The findings do more than clarify how ketamine works. They may also have practical clinical value. PET imaging of AMPAR could potentially serve as a biomarker that helps doctors evaluate and predict how individuals with TRD will respond to ketamine treatment.

Because many patients do not respond to standard antidepressants, identifying reliable biological markers for treatment response remains an important goal in mental health care.

Toward More Personalized Depression Treatments

By allowing scientists to directly observe AMPAR activity in the living human brain, this research helps bridge a long-standing gap between laboratory research and clinical psychiatry. The results identify AMPAR modulation as a central mechanism behind ketamine's rapid antidepressant effects and suggest that AMPAR PET imaging could guide more personalized treatment strategies in the future.

Ultimately, this work could support the development of more precise therapies for people living with treatment-resistant depression.

This work was supported by the Ministry of Education, Culture, Sports, Science and Technology (Special Coordination Funds for Promoting Science and Technology); the Japan Agency for Medical Research and Development (AMED) (grant numbers: JP18dm0207023, JP19dm0207072, JP24wm0625304, JP25gm7010019, and JP20dm0107124); the Japan Society for the Promotion of Science KAKENHI (grant numbers: 22H03001, 20H00549, 20H05922, 23K10432, 19H03587, 20K20603, 22K15793, and 21K07508); the Takeda Science Foundation; the Keio Next-Generation Research Project Program; the SENSHIN Medical Research Foundation; and the Japan Research Foundation for Clinical Pharmacology.